Neurosense Therapeutics is trading 7.3% up at $0.52 as bargain hunters move in following a period of sharp declines.
- The stock hit a low of $0.48 on July 29, 2026, after several days of selling pressure and general biotech sector weakness.
- Market commentary suggests the rebound is driven by opportunistic buying and technical interest rather than any new fundamental company announcements or catalysts.